Top 12 Clinical Research Organisations (CROs) in 2023
Feb 23, 2023 · The global clinical trials market was estimated to be worth $38.7 billion in 2021 and is expected to reach £52 billion by 2026. In this article, we look at the top 12 CROs in the world, highlighting the companies driving this considerable growth and accelerating research and development across the globe.. ICON. Recognised as the world’s largest and most comprehensive CRO powered by ...
PharmiWeb.com: The Heart of Life Sciences on the Web
PharmiWeb.com - Global pharma news from the pharmaceutical industry, biotech, clinical research, life science & healthcare. Pharma Events Listings, Pharma Company Directory & pharma jobs.
Biosimilars Market Role in Reducing Healthcare Costs and …
Dec 9, 2024 · The global biosimilars market is witnessing remarkable growth, driven by factors such as cost efficiency, increased demand for accessible healthcare solutions, and the expiration of patents for branded biologic drugs. With a market that was valued at approximately USD 20.4 billion in 2021, the biosimilars market is expected to expand significantly, reaching more than USD 85 billion by the end ...
Trading update for year ending 31 December 2024 and an early …
Dec 10, 2024 · The Company reports that, following the operational reorganisation at the end of Q3 2024, the highest levels of both sales orders and book-to-bill ratio this year was recorded in October. Encouragingly, sales orders secured during the second half of 2024 included an increasing number of multi-product contracts ...
Gerresheimer successfully completes acquisition of Blitz LuxCo Sarl ...
Dec 11, 2024 · EQS-News: Gerresheimer AG / Key word(s): Mergers & AcquisitionsGerresheimer successfully completes acquisition of Blitz LuxCo Sarl, the holding company of the Bormioli Pharma Group 11.12.2024 / 08:00 CET/CESTThe issuer is solely responsible for the content of this announcement.Gerresheimer successfully completes...
BRAIN Biotech AG Sharpens Focus on Profitable Growth
Dec 12, 2024 · EQS-News: BRAIN Biotech AG / Key word(s): Capital Markets DayBRAIN Biotech AG Sharpens Focus on Profitable Growth 12.12.2024 / 09:00 CET/CESTThe issuer is solely responsible for the content of this announcement.BRAIN Biotech AG Sharpens Focus on Profitable Growth Combination of BioProducts segment and BioScience Zwi...
HUTCHMED Announces Breakthrough Therapy Designation in …
Dec 12, 2024 · Hong Kong, Shanghai & Florham Park, NJ — Thursday, December 12, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that the Center for Drug Evaluation of China’s National Medical Products Administration (“NMPA”) has granted Breakthrough Therapy Designation (“BTD”) to the combination of ORPATHYS ® (savolitinib) and TAGRISSO ® (osimertinib ...
Bionical Emas sells EMAS Pharma to Kester Capital following …
Dec 9, 2024 · Bionical Emas (“Bionical”) or (“the Company”), the Early Access Programs and Clinical Trial Supply business, is selling its Clinical Development division, EMAS Pharma, to Kester Capital and an incoming executive team. The decision to sell comes after a strategic review held earlier this year. Financial terms have ...
Sanofi launches high-dose egg-based quadrivalent influenza …
Oct 15, 2024 · Sanofi launches high-dose egg-based quadrivalent influenza vaccine (QIV-HD) in the UK · Developed with a higher antigen content to increase protection in older adults, a population at greater risk of severe complications from infection.· ...
ConTIPI Medical & EVERSANA Announce U.S. Commercial Launch …
CHICAGO – December 10, 2024 – ConTIPI Medical, an innovator in providing non-surgical and disposable solutions for women with various pelvic floor dysfunctions, and EVERSANA, a leading provider of global commercial services to the life sciences industry, today announced the United States commercial launch of ProVate to help women experiencing pelvic organ prolapse (POP).